← Back to Search

Glutamate receptor antagonist

Memantine for Trichotillomania

Phase 2
Waitlist Available
Led By Jon Grant, JD, MD, MPH
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

Study Summary

This trial is testing whether memantine can help improve symptoms of schizophrenia. It is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either memantine or placebo on a 1:1 basis.

Eligible Conditions
  • Trichotillomania
  • Skin Picking Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
NIMH Symptom Severity Scale (for TTM or Skin Picking)
Secondary outcome measures
Clinical Global Impressions-Improvement Scale (CGI-I)
Hamilton Anxiety Rating Scale
Hamilton Depression Rating Scale
+3 more

Side effects data

From 2019 Phase 4 trial • 115 Patients • NCT01902004
23%
Sleepiness/Sedation
10%
Headache
8%
Tension/Inner Unrest
8%
Reduced Salivation
8%
Concentration Difficulties
8%
Diminished Sexual Drive
6%
Asthenia/Lassitude/Increased Fatigability
6%
Constipation
6%
Polyuria/Polydipsia
6%
Orthostatic Dizziness
4%
Nausea/Vomiting
4%
Erectile Dysfunction
4%
Failing Memory
2%
Diarrhea
2%
Increased Duration of Sleep
2%
Reduced Duration of Sleep
2%
Increased Dream Activity
2%
Accomodation Disturbance
2%
Increased Tendancy to Sweating
2%
Weight Gain
2%
Ejaculatory Dysfunction
2%
Micturtion Disturbances
100%
80%
60%
40%
20%
0%
Study treatment Arm
Escitalopram and Placebo
Escitalopram and Memantine

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MemantineExperimental Treatment1 Intervention
10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks
Group II: PlaceboPlacebo Group1 Intervention
10mg once daily of placebo for two weeks, then 20mg for the remaining six weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Memantine
FDA approved

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,003 Previous Clinical Trials
819,649 Total Patients Enrolled
10 Trials studying Trichotillomania
404 Patients Enrolled for Trichotillomania
Jon Grant, JD, MD, MPHPrincipal InvestigatorUniversity of Chicago

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Tennessee
New York
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
University of Chicago
Recent research and studies
Journal of Clinical PsychopharmacologyJournal
A Double-blind, Placebo-controlled Trial of Lamotrigine for Pathological Skin Picking
Grant, Jon E., Brian L. Odlaug, Samuel R. Chamberlain, and Suck Won Kim. 2010. “A Double-blind, Placebo-controlled Trial of Lamotrigine for Pathological Skin Picking”. Journal of Clinical Psychopharmacology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/jcp.0b013e3181e617a1.
Psychological ReportsJournal
The Tridimensional Personality Questionnaire: U.S. Normative Data
Cloninger, C. Robert, Thomas R. Przybeck, and Dragan M. Svrakic. 1991. “The Tridimensional Personality Questionnaire: U.S. Normative Data”. Psychological Reports. SAGE Publications. doi:10.2466/pr0.1991.69.3.1047.
NeuropsychopharmacologyJournal
White Matter Abnormalities in Skin Picking Disorder: A Diffusion Tensor Imaging Study
Grant, Jon E, Brian L Odlaug, Adam Hampshire, Liana RN Schreiber, and Samuel R Chamberlain. 2012. “White Matter Abnormalities in Skin Picking Disorder: A Diffusion Tensor Imaging Study”. Neuropsychopharmacology. Springer Science and Business Media LLC. doi:10.1038/npp.2012.241.
nJournal
<i>n</i>-acetylcysteine in the Treatment of Excoriation Disorder
Grant, Jon E., Samuel R. Chamberlain, Sarah A. Redden, Eric W. Leppink, Brian L. Odlaug, and Suck Won Kim. 2016. “n-acetylcysteine in the Treatment of Excoriation Disorder”. JAMA Psychiatry. American Medical Association (AMA). doi:10.1001/jamapsychiatry.2016.0060.
~26 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top